What does the FIGARO trial reveal about predictors of outcome post-transplant?

During the 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings), the MDS Hub was pleased to speak with Charles Craddock, Queen Elizabeth Hospital Birmingham, Birmingham, UK. We asked, What does the FIGARO trial reveal about predictors of outcome post-transplant?

Craddock begins by outlining the trial aims and design, which investigated the use of the FLAMSA-Bu conditioning regimen in adult patients with AML. Craddock outlines the study results, noting that the presence of pretransplant measurable residual disease (MRD) is still associated with increased risk of relapse, and the most important predictor of outcome. Finally, Craddock discusses full donor T-cell chimerism, and reduced intensity conditioning (RIC) allograft strategies and mechanisms.